Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1899-1901

  Chen, Ya Ting ^a   Hayden, Cheryl L ^a   Marchand, Kathleen J ^a   Makuch, Robert W ^a  

^a NONE

Author keywords

Bladder neoplasms; Carcinoma; Nuclear matrix; Transitional cell; Tumor markers, biological; Urine

Indexed keywords

NUCLEAR PROTEIN; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CELL NUCLEUS MATRIX; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT CANCER;

EID: 0030763879     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64164-8     Document Type: Article

References (8)

1. Berezney, R.: The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J. Cell Biochem., 47: 109, 1991.
2. Fey, E. G., Bangs, P., Sparks, C. and Odgren, P.: The nuclear matrix: denning structural and functional roles. Crit. Rev. Eukary. Gene Exp., 1: 127, 1991.
3. Merrifield, S. A., Roos, R. F., Shapiro, K. D. and Briggman, J. V.: The performance of the NMP22® test kit: a quantitative enzyme immunoassay for bladder cancer. XXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine, Montreal, Canada, September 10-13, 1995.
4. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E., Pasciak, R. M., Reservitz, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., Thiel, R. P. and Hayden, C. L.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363, 1996.
5. Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P. H., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rukstalis, D. B., Sarosdy, M. F., Soloway, M. S., Thiel, R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol., 156: 1280, 1996.
6. Abel, P. D.: Prognostic indices in transitional cell carcinoma of the bladder. Brit. J. Urol., 62: 103, 1988.
7. Badalament, R. A., Hermansen, D. K., Kimmel, M., Hay, H., Herr, H. W., Fair, W. R., Whitmore, W. F., Jr. and Melamed, M. R.: The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer, 60: 1423, 1987.
8. Marchand, K. J., Stolarek, S., Nanez, E., Chandler, C., Stribling, L., Lange, J., Staab, M. J., Erickson, B. and Clayton, M.: Patient compliance of a take home urine collection kit for the Matritech NMP22 test kit. XXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine, Montreal, Canada, September 10-13, 1995.